VA Study Offers New Hope for Prostate Cancer Patients

Patients with aggressive prostate cancer just got some much-needed good news about which treatment to choose when their disease progresses.

A new study published in JAMA Network Open discovered that men with metastatic castration-resistant prostate cancer who previously responded well to the chemotherapy drug docetaxel should consider using it again rather than switching to a newer alternative called cabazitaxel. The research showed patients who stuck with docetaxel lived nearly three months longer.

That may sound modest, but for patients facing one of the deadliest forms of cancer, those extra months matter enormously. The median survival was 12.3 months for patients who received docetaxel again compared to 9.6 months for those who switched to cabazitaxel.

Dr. Rachel Ramoni, director of the Kaiser Permanente Division of Research and co-author of the study, emphasized the importance of giving patients clear options. "The findings highlight a clinically important option for patients who are often faced with multiple treatment decisions," she said.

The research team faced a common challenge in modern cancer care. With dozens of approved treatments now available for prostate cancer, conducting traditional clinical trials that compare different therapy sequences has become nearly impossible.

So researchers took a different approach. They analyzed electronic health records from 669 patients in the Veterans Affairs system, using sophisticated statistical methods to compare outcomes between those who received docetaxel twice and those who switched to cabazitaxel.

The results revealed something else encouraging. Patients who received docetaxel for a second time also needed less supportive care, meaning they experienced fewer difficult side effects.

The Bright Side

This study represents a breakthrough in how we can use real-world medical data to answer crucial questions for patients. Traditional clinical trials comparing these two treatments would have been extremely difficult to conduct and might never have happened.

Both the VA and Kaiser Permanente are integrated health care systems with robust electronic health records covering millions of patients. This treasure trove of data contains answers to treatment questions that researchers couldn't explore any other way.

Ramoni pointed out that this type of research is only possible at scale in systems like the VA and Kaiser Permanente. "Both systems are able to use their data to conduct large real-world studies that could be carried out in few other locations," she explained.

Prostate cancer is the second leading cause of cancer deaths among American men. As treatments multiply and become more complex, patients and doctors increasingly need evidence-based guidance on which therapies work best in specific situations.

This research shows that the answers may already exist within the electronic health records being generated every day in hospitals and clinics across the country.